onAIRR 4: Understanding and engineering immune repertoires with Dr. Jacob Glanville

50:35
 
分享
 

Manage episode 327115613 series 3328144
由Player FM以及我们的用户群所搜索的AIRR-Community — 版权由出版商所拥有,而不是Player FM,音频直接从出版商的伺服器串流. 点击订阅按钮以查看Player FM更新,或粘贴收取点链接到其他播客应用程序里。

Dr. Jacob Glanville is founder and CEO of Centivax and founder of Distributed Bio, acquired by Charles River in 2021. His work focuses on understanding and engineering the repertoires of T and B cells to improve the response to pathogens. In this episode we discuss how to analyze receptor specificity and use this to create therapeutic antibodies and optimize vaccine response.

AIRR Community Meeting VI: “Exploring New Frontiers”: https://www.antibodysociety.org/the-airr-community/meetings/airr-community-meeting-vi-exploring-new-frontiers

iReceptor+ Seminar Series: http://www.ireceptor-plus.com/news-and-events/seminars

Comments are welcome to the inbox of onairr@airr-community.org or on social media under the hashtag #onAIRR. Further information can be found here: https://www.antibodysociety.org/the-airr-community/airr-c-podcast

9集单集